Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUR108 · 1 trial · 1 indication
Assess dose limiliting toxicities of AUR108
Number of participants with TEAEs
Maximum Concentration of AUR108
Tmax in hours
Area under the curve (AUC) of AUR108 in h\* ng/mL
Terminal elimination half-life of AUR 108 in hours
Compare in fast and fed conditions
Compare Tmax in fast and fed conditions
Compare AUC in fast and fed conditions
| Arm | Type | Description |
|---|---|---|
| AUR108, 50mg to 300mg | EXPERIMENTAL | Currently, planned dose levels are 50,90,150,220,300 mg will be administered in 3+/4- regimen. |
| Name | Type | Description |
|---|---|---|
| AUR108 | DRUG | 3 Days dosing, and 4 days no dose in a week |
Inclusion Criteria: 1. Males or females ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 3. Acceptable bone marrow and organ function at screening as described below: 1. ANC ≥ 1000/μL (without WBC growth factor support) 2. Platelet count ≥ 75,000/μL...
AUR108 is an investigational small molecule being studied for the treatment of relapsed advanced lymphomas. It is currently in Phase 1 clinical development, with an ongoing trial evaluating its safety and efficacy in patients with this condition.
AUR108 targets dihydroorotate dehydrogenase (DHODH), an enzyme involved in pyrimidine synthesis. By inhibiting DHODH, the drug aims to disrupt cellular processes relevant to cancer cell proliferation in relapsed advanced lymphomas.
AUR108 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials for this investigational oncology drug.
AUR108 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients to evaluate its safety and efficacy.
AUR108 is being studied in a Phase 1 clinical trial with the identifier NCT05984147, titled 'A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)'. This trial is recruiting participants in India and aims to enroll 40 patients.